Imugene is an Australian biotechnology company with operations in the U.S. and in Europe, developing cancer immunotherapies targeting B-cell peptide vaccines.
Imugene adds key members to its scientific advisory board to advance company forward
Quick facts: Imugene Limited
Price: 0.495 AUD
Market Cap: $2.7 billion
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...FOR OUR FULL DISCLAIMER CLICK HERE